Clinical trial NCT04808115: IIT PH1 KDS-1001 in Patients With CML
Official title: A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients With Chronic Myeloid Leukemia (CML) and Molecular Residual Disease After Tyrosine Kinase Inhibitor (TKI) Therapy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: CML (Chronic Myelogenous Leukemia
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: Kiadis Pharma
First posted: 2021-03-22
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This open label, non-randomized, prospective phase I study is designed to evaluate if the addition of natural killer cell therapy (KDS-1001) to tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) patients with persistent or recurrent molecular residual disease (MRD) after at least one year of TKI therapy will allow patients to achieve RT-PCR negativity (MRD negative). This may have implications for future TKI cessation studies.


Eligibility criteria: Inclusion Criteria:

1. Patients with non-blast phase CML by standard definition. This should be confirmed by presence of the Philadelphia chromosome or variants of the (9;22) translocation by cytogenetics, FISH or with a positive RT-PCR for BCR-ABL. Repeat marrow not required for enrollment although documentation of current chronic phase disease is required.

   Chronic Phase CML is defined as follows:
   1. \<15% blasts in peripheral blood and marrow
   2. \<30% blasts plus promyelocytes in peripheral blood and marrow
   3. \<20% basophils in peripheral blood
   4. \>100 x 109/L platelets
   5. No evidence of extramedullary leukemic involvement with the exception of hepatosplenomegaly.

   Accelerated Phase CML is defined as follows:
   1. \<30% blasts in blood, marrow or both
   2. No evidence of extramedullary leukemic involvement with the exception of hepatosplenomegaly.
2. \> 18 years of age and able to provide informed consent
3. Patients must have been on TKI therapy for CML for at least 1 year prior to enrollment at minimum goal doses.

   Imatinib 300mg PO daily Dasatinib 70mg PO daily Nilotinib 200mg PO BID Bosutinib 300mg PO daily Ponatinib 30mg PO daily Lower than goal doses are allowed IF documented by the treating physician that the goal dose was not tolerable due to toxicity.
4. Patient must have been on their most recent TKI consistently for at least 6 months prior to enrollment on study
5. Must be expected to remain on current TKI for at least 6 months following last infusion, unless there is progression of disease.
6. Detectable BCR-ABL transcripts measured by RT-PCR at a CLIA-approved laboratory and reported on the IS with a value of \>0.01% within 28 days prior to study enrollment. The chosen RT-PCR test must be sensitive enough to detect a 4.5 log reduction in BCR/ABL transcripts measured in peripheral blood.
7. Performance status must be ECOG PS 0, 1, or 2.
8. Woman of childbearing potential and is willing to use 2 highly effective methods of contraception while receiving study treatment and for an additional 3 months after the last dose of protocol-specified therapy. Male who has a female partner of childbearing potential, and is willing to use 2 highly effective forms of contraception for at least an additional 3 months after the last dose of protocol-specified therapy.

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study:

1. Current blast crisis phase disease by standard definition from the NCCN
2. Pregnant or lactating females
3. On other investigational agents for CML within 4 weeks of study enrollment
4. Platelets of \<50,000/mm3, ANC \<500/mm3 or hemoglobin \< 7.5 g.dL
5. Abnormal screening laboratory values as defined below:

   1. AST (SGOT) and/or ALT (SGPT) and/or alkaline phosphatase ≥ 5 x upper limit of normal (ULN)
   2. Total bilirubin \>1.5 x ULN (unless related to Gilbert´s or Meulengracht disease or leukemic infiltration)
   3. Creatinine ≥ 3 ULN or creatinine clearance \< 50 mL/min (calculated)
   4. Those with residual toxicity of \>grade 1 from prior therapy in areas that may be expected to worsen over time; those with residual toxicities of grade 2 which are stable prior to enrollment and the natural history of which would be expected to be 'no change' over time are allowed; those with grade 3 or 4 residual toxicities are not.
6. Positive test for human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS)
7. Positive hepatitis B virus (HBV) or hepatitis C virus (HCV) indicating acute or chronic infection (those with prior infection that is now post treatment and PCR negative are allowed)
8. Current use of immunosuppressive medications at the time of study enrollment and within 2 weeks of any study treatments, except:

   1. Intranasal, inhaled, topical steroids, or local steroid injection
   2. Systemic corticosteroids at physiologic doses ≤10 mg/day of prednisone or equivalent
   3. Steroids as premedication for hypersensitivity reactions at physiologic doses ≤10 mg/day of prednisone or equivalent
9. Patients with other major medical or psychiatric illnesses, which the treating physician feels, could seriously compromise tolerance or compliance to this protocol.
10. Diagnosis of prior immunodeficiency or organ transplant requiring immunosuppressive therapy
11. Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, deep vein thrombosis, or symptomatic pulmonary embolism
12. Known prior or suspected hypersensitivity to study drugs or any component in their formulations
13. Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible
14. Diagnosis of any other malignancy within 3 years, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the breast or of the cervix, low grade prostate cancer on surveillance without any plans for treatment intervention, or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms
15. Active infection requiring systemic therapy

Primary outcomes:
measure: Molecular Response
timeFrame: End of Treatment up to two weeks
measure: Safety of KDS-1001
timeFrame: End of Study up to two years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Assistant Professor of Medicine, Hematologic Malignancies & Cell Therapy
name: Lindsay Rein, MD
role: PRINCIPAL_INVESTIGATOR
References: